Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Galectin-3 is upregulated in frontotemporal dementia patients with subtype specificity.

Alzheimer's & dementia : the journal of the Alzheimer's Association - 1 Mar 2024

Borrego-Écija Sergi, Pérez-Millan Agnès, Antonell Anna, Fort-Aznar Laura, Kaya-Tilki Elif, León-Halcón Alberto, Lladó Albert, Molina-Porcel Laura, Balasa Mircea, Juncà-Parella Jordi, Vitorica Javier, Venero Jose Luis, Deierborg Tomas, Boza-Serrano Antonio, Sánchez-Valle Raquel

Abstract excerpt

INTRODUCTION: Neuroinflammation is a major contributor to the progression of frontotemporal dementia (FTD). Galectin-3 (Gal-3), a microglial activation regulator, holds promise as a therapeutic target and potential biomarker. Our study aimed to investigate Gal-3 levels in patients with FTD and assess its diagnostic potential. METHODS: We examined Gal-3 levels in brain, serum, and cerebrospinal fluid (CSF) samples...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Brain

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to C9orf72 Protein

Share to Frontotemporal Dementia

Share to Galectin 3

Share to Mutation

Share to tau Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 38018380
DOI: 10.1002/alz.13536
PMCID: PMC10984429

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Galectin-3 is upregulated in frontotemporal dementia patients with subtype specificity.PMID 38018380Read ↗

Galectin-3 drives neuroinflammatory amyloid remodeling by stabilizing intermediate Aβ species and altering lysosomal processingSemantic proximity Read ↗

Galectin-3 drives tau-associated neuroinflammation, white matter degeneration and proteomic dysregulationSemantic proximity Read ↗

Galectin-3, A Novel Endogenous Trem2 Ligand, Regulates Inflammatory Response and Aβ Fibrilation in Alzheimer’s DiseaseSemantic proximity Read ↗

Protective Role of Galectin-3 in Prion Disease Through Regulation of Microglial PrP <sup>Sc</sup> UptakeSemantic proximity Read ↗

Blood-Based Biomarkers in Frontotemporal Dementia: A Narrative Review.Semantic proximity Read ↗

Plasma inflammation for predicting phenotypic conversion and clinical progression of autosomal dominant frontotemporal lobar degeneration.Semantic proximity Read ↗

CSF 14-3-3ζ is associated with tau pathology and elevated across the Alzheimer’s disease continuumSemantic proximity Read ↗

Neurofilament light chain: a biomarker for genetic frontotemporal dementiaSemantic proximity Read ↗

CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers.Semantic proximity Read ↗

Sweet Aging: Glycocalyx and Galectins in CNS Aging and Neurodegenerative DisordersSemantic proximity Read ↗

Serum Cathepsin S Levels Do Not Show Alterations in Different Clinical, Neuropathological, or Genetic Subtypes of Frontotemporal Dementia Patients nor in Comparison to Healthy Control Individuals.Semantic proximity Read ↗

Galectin-3 promotes brain injury by modulating the phenotype of microglia via binding TLR-4 after intracerebral hemorrhage.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.